The Department of Clinical Pharmacy and Pharmacology (CPP) is responsible for the pharmaceutical care of UMCG patients, the pharmacy and pharmacology education program for pharmacy and medical students and for research. CPP has about 220 collaborators working in the three sections: patient care; education; research. Within CPP there is a dedicated sub-department responsible for the manufacturing of ad-hoc medication and the development and manufacturing of special products for clinical trials, including biotechnological products.

The Department of Clinical Pharmacy and Pharmacology holds a manufacturing license for the production, quality control and release of investigational medicinal products, including biologicals, ATMPs, and tracers, under Good Manufacturing Practices (GMP).

The biotechnology and ATMP unit is a dedicated unit in which a range of biotechnological products can be manufactured, such as:

  • Master/working cell banks (MCBs/WCBs)
  • Recombinant proteins from micro-organisms
  • Recombinant proteins from mammalian cells
  • Vaccines (viral, protein or bacterial)
  • ATMPs (cell and gene therapy products)

These services include process development, optimization, validation, (contract) manufacturing under EU-GMP conditions and the release of the drug product. Furthermore, the QC laboratory can be contracted for release testing of the final Drug Product. The facility is cGMP certified and licensed since 2008 by the Dutch Authorities under registration number 108964 F.